Immunomedics Announces Pricing of Public Offering of Common Stock

As I recently posted, Immunomedics had a horrible 2019 with the rejection of their ADC. But 2020 is looking real good. There is no doubt that this ADC sacituzumab govetecan will have an impact as it target the deadly triple-negative breast cancer phenotype. Now the company want to capitalize on this drug monetarily and this could be a good investment option for people investing in the biotech sector.